Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical‐stage, immuno‐oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel, non‐chemotherapy, immune‐enhanced combination treatments for patients with solid tumor cancers. Checkpoint’s broad pipeline consists of fully‐human, immuno‐oncology and checkpoint inhibitor antibodies licensed from the Dana‐Farber Cancer Institute that target programmed death‐ligand 1 (“PD‐L1”); glucocorticoid‐induced TNFR‐related protein (“GITR”); and carbonic anhydrase IX (“CAIX”). In addition, Checkpoint is developing three oral, small‐molecule, targeted anti‐cancer agents that inhibit epidermal growth‐factor receptor (“EGFR”) mutations, the bromodomain and extra‐terminal (“BET”) protein BRD4, and poly (ADP‐ribose) polymerase (“PARP”). Checkpoint will also seek to expand its pipeline to create additional proprietary combination therapies that leverage the immune system and complementary mechanisms. Checkpoint is a majority controlled subsidiary of Fortress Biotech, Inc.
- Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial
- Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
- UroGen Pharma Expands Clinical Development Leadership Team